Morphic only had eyes for Eli Lilly. While some takeover tales have casts of Shakespearean breadth, Lilly’s $3.2 billion Morphic buyout is a simpler story of two companies gradually closing the gap ...
Monday, Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion. Morphic is a biopharmaceutical company ...
Eli Lilly has immunology and inflammation products administered by injection, but the pharmaceutical giant is among the companies interested in bringing patients more convenient pill formulations. Its ...
AbbVie is ditching work on all the alpha V beta 6 (αvβ6) inhibitors that it paid $20 million to license from Morphic Therapeutic in 2020. The Big Pharma is culling the work because of a suspected ...
INDIANAPOLIS and WALTHAM, Mass., July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic ...
Leerink Partners analyst Thomas Smith has reiterated their bullish stance on MORF stock, giving a Buy rating on February 22. Thomas Smith has given his Buy rating due to a combination of factors ...
WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic ...
BOSTON, Aug. 5, 2025 /PRNewswire/ -- Morphic Medical, an innovative MedTech company that has pioneered minimally invasive treatment of obesity and cardiometabolic disorders, today announced a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback